hepatocellular carcinoma;F-box and leucine-rich repeat 6 (FBXL6) activation;Kirsten rat sarcoma (KRAS)^G12D mutation;Mitogen-activated protein kinase (MEK)/mammalian target of rapamycin (mTOR) pathway;metastasis